ecancermedicalscience

Review

Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis

16 Aug 2021
Victor Hugo Fonseca de Jesus, Rachel P Riechelmann

Background: There are no head-to-head comparisons evaluating the efficacy of the main polychemotherapy regimens used for patients with pancreatic cancer in the adjuvant setting. We aimed to describe the relative efficacy of modified FOLFIRINOX (mFOLFIRINOX), gemcitabine plus capecitabine (GEM-CAP) and gemcitabine plus nab-paclitaxel (GEM-NAB) in this setting using a Bayesian network approach.

Methods: We collected data from the ESPAC-4, PRODIGE 24 and APACT trials. Disease-free survival (DFS), according to the investigators, and overall survival (OS) for the three polychemotherapy regimens were compared using gemcitabine as the reference arm. We ran Markov chain Monte Carlo simulations with a fixed-effect model to generate the posterior distribution of the hazard ratios (HRs) using non-informative priors. Relative efficacy was measured by HRs, surface under cumulative ranking and rankograms.

Results: mFOLFIRINOX was the chemotherapy regimen most likely to be the most effective in the adjuvant setting (98.9% and 89.6% probability for DFS and OS, respectively). GEM-NAB marginally improved DFS (HR = 0.97, 95% credible interval (95% CrI) = 0.77–1.21) and OS (HR = 0.98, 95% CrI = 0.76–1.25) when compared to GEM-CAP. However, GEM-NAB had the highest chances of being the second most active chemotherapy regimen (61.4% and 52.5% probability for DFS and OS, respectively), whereas GEM-CAP was less likely to represent the second most active regimen (37.7% and 40.1% probability for DFS and OS, respectively).

Conclusion: For patients eligible and fit enough to undergo adjuvant treatment with mFOLFIRINOX, this constitutes the treatment of choice. For those with contraindications to mFOLFIRINOX, while both GEM-NAB and GEM-CAP can be considered appropriate alternatives, GEM-NAB is likely the most effective regimen.

Related Articles

Marina Junqueira de Almeida, Marcos Pedro Guedes Camandaroba, Antonio Paulo Nassar Jr, Victor Hugo Fonseca de Jesus
Andry Lalaina Rinà Rakotozafindrabe, Chantelli Iamblaudiot Razafindrazoto, Domoina Harivonjy Hasina Laingonirina, Tojonokoloina Benjamin Ralideramanambina, Behoavy Mahafaly Ralaizanaka, Sonny Maherison, Jolivet Auguste Rakotomalala, Nitah Harivony Randriamifidy, Anjaramalala Sitraka Rasolonjatovo, Tovo Harimanana Rabenjanahary, Soloniaina Hélio Razafimahefa, Rado Manitrala Ramanampamonjy
Debdeep Dey, Bhagat Singh Lali, Paromita Roy, Divya Midha, Indu Arun, Lateef Zameer, Anand Bardia, Geetashree Mukherjee
Tsion Afework, Birtukan Seid, Aderaw Anteneh, Wondimu Ayele, Seifu Hagos Gebreyesus, Bilal Shikur Endris
Juan Francisco Olivos Gonzáles, Rodrigo Arroyo-Gárate, Miguel Angel Leon Estrella, Gustavo Cerrillo, Stefanie Campos Medina
Hasan Nassereldine, Hussein Awada, Adel Hajj Ali, Mohammad Zeineddine, Zahy Abdul Sater, Yasser Shaib